Monitoring of the Ischemic Stroke Patient Through the Use of New Serum Biomarkers and MRI Imaging

NCT ID: NCT05812846

Last Updated: 2023-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

135 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-04

Study Completion Date

2023-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of this study will be the evaluation (by ELISA quantification and quantitative RT-PCR) of circulating biomarkers of damage and regeneration in patients affected by ischemic stroke. The biomarker levels will be measured from the acute event (48h) and in subsequent 4 times (7 days, 30 days, 90 days, 180 days) following hospitalization, up to 6 months after the acute event. These data will then be correlated for all five times with the clinical scales normally used for patient evaluation and will also be associated with MRI-DTI measurements performed in the post-acute (30 days) and post-discharge (180 days) phase.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In current clinical practice, outcome's assessment after stroke and patients' monitoring during rehabilitation rely on scores in clinical scales and instrumental evaluations (electrophysiological evaluations and MRI imaging). This approach follows current guidelines but has some limitations:

* subjectivity of the patient's clinical evaluation and instrumental data's interpretation
* poor prognostic value of clinical scales;
* poor prognostic value of instrumental measurements;
* difficulty in standardizing and automating clinical/instrumental assessments;
* difficulty in evaluating medical services on a large scale due to the lack of discrete values of treatment efficacy.

The identification and validation of reliable and accessible biomarkers associated with patients' functional recovery could improve their care but still remains a clinical challenge.

Aim of this study will be to measure the levels of circulating biomarkers of brain damage and regeneration in patients affected by ischemic stroke, and to evaluate their prognostic relevance over a 6-month follow-up. Biomarkers' levels will be measured by ELISA and quantitative RT-PCR from the acute event (within 24h from symptoms onset) and in subsequent 4 time-points (7 days, 30 days, 90 days, 180 days post-stroke). Obtained data will be correlated with clinical scales used for patient evaluation and will be associated with MRI-DTI measurements performed in the post-acute (30 days) and post-discharge (180 days) phase.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* First occurrence of brain injury, confirmed on CT imaging, determined by ischemic stroke
* Patient able to sign an informed consent, alternatively legal representative or relative

Exclusion Criteria

* Previous ischemic events
* Previous head trauma of any entity
* New onset of acute events during the study
* Previous illness, diagnosis or suspicion of current illness with central nervous system involvement
* Diagnosis of cognitive impairment prior to the acute event (MMSE \< 24)
* Need for walking assistance prior to the acute event
* Diagnosis of autoimmune diseases
* Diagnosis of haematological or oncological disease
* Diagnosis of a psychiatric condition: bipolar disorder, psychosis, schizophrenia or suicidal ideation
* Subjects with relative and absolute contraindications to magnetic resonance imaging.
* Life expectancy less than 1 year
* Dependence or abuse of alcohol, drugs or psychotropics prior to the acute event
* Pregnancy in progress
* Severe renal or hepatic insufficiency (Renal disease \> II stage, Child-Plugh score \>5)
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istituti Clinici Scientifici Maugeri SpA

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istituti Clinici Scientifici Maugeri SpA

Pavia, Lombardy, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2250

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Diffusion Spectroscopy in Stroke
NCT02833961 COMPLETED NA